Остеопороз и остеопатии

Расширенный поиск


Полный текст:

Список литературы

1. Баркова Т.В., Беневоленская Л.И., Бакулин А.В. Изучение эффективности и переносимости препарата фосамакс у женщин с постменопаузальным остеопорозом по сравнению с плацебо // Остеопороз и остеопатии. 1998, No 2. С. 33-36.

2. Рожинская Л.Я., Дзеранова Л.К., Марова Е.И. и др. Результаты лечения постменопаузального остеопороза бисфосфонатом-фосамаксом // Остеопороз и остеопатии. 1998, No 2. С. 28-32.

3. Скрипникова И.А., Косматова О.В. Результаты длительного лечения постменопаузального остеопороза бисфосфонатом-фосамаксом // Остеопороз и остеопатии. 2004, No 1. С. 16-19.

4. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman AJosse R. et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis// New England J. Medicine 1997. V. 337, 382-387.

5. Adachi J.D., Saag K.G., Delmas P.D., Liberman U.A., Emkey R.D., Seeman E. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial// J. Arthritis Rheumatism, 2001; Vol. 44: 202-211.

6. Adami S., Passeri M., Ortolani S. et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers in postmenopausal women with osteoporosis// J. Bone, 1995. Vol. 17: 383-390.

7. American association of clinical endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition with selected updates for 2003 // J. Endocrine Practice, 2003. Vol. 9, pp. 544-564.

8. American Medical Association (AMA) guidelines postmenopausal osteoporosis. 2003 // www. part3/index.htm

9. Amin S., La Valley M.P., Simms R.W., Felson D.T. // The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression // J. Bone Mineralal Research, 2002. Vol.17: 1512-1526.

10. Bauss F., Muhlbauer R.C.: Ibandronate, monosodium salt, monohydrate. Drug of the Future, 1994; 19(1): 13-16.

11. Bell N.H., Bilezikian J.P., Bone H.G. III, Kaur A., Maragoto A., Santora A.C. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women // J. Clinical Endocrinology Metabolism, 2002. Vol. 87: 2792-2797.

12. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures// J. Lancet 1996. Vol. 348: 1535-1541.

13. Black D.M., Greenspan S.L., Ensrud K.I. et al. The effects of Parathyroid hormone and Alendronate alone or in combination in postmenopausal osteoporosis // New England J Medicine 2003. Vol. 349, pp. 1207-1215.

14. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner M.C., Hochberg M.C., Nevitt M.C., Suryawanshi S., Cummings S.R. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial // J. Clinical Endocrinology Metabolism, 2000. Vol. 85: 4118-4124.

15. Body J., Gaich G.A., Scheele W.H., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis // J. Clinical Endocrinology Metabolism, 2002. Vol. 87: 4528-4535.

16. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women // J. Bone, 2000. Vol. 27: 687-694.

17. Bone H.G., Downs R.W., Tucci J.R. et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women // J. Clinical Endocrinology Metabolism 1997. Vol. 82: 265-74.

18. Bone H.G., Greenspan S.L., McKeever C. et al. Alendronate and estrogen effects in postmenopausal women with low bone mineraldensity // J. Clinical Endocrinology Metabolism 2000. Vol. 85: 720-726.

19. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., et al. Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women // New England J. Medicine, 2004. Vol. 350: 1189-1199.

20. Bonnick S., Rosen C., Mako B. et al. Alendronate vs calcium for treatment of osteoporosis in postmenopausal women // ASBMR-ISBM, 2001, F280.

21. Chesnut H. C. III, Skag A., Christiansen C., Recker R., Stakkestad J. A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R. C., Delmas P. D. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis // J. Bone Mineral Research 2004. Vol. 19: 1241-1249.

22. Chesnut C.H., McClung M.R., Ensrud K.E. et al. Alendronate treatment of the postmenopausal osteoporotic women: effects of multiple dosadges on bone mass and bone remodeling // American J. Medicine, 1995. Vol. 99: 144-152.

23. Christiansen C., Christensen M.S., Transbol I.B. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy // J. Lancet 1981. Vol. 1 (8218): 459-461.

24. Cortet B., Hachulla E., Barton et al. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases: A randomized study // Revue du Rhumatisme English Ed, 1999. Vol. 66: 214-219.

25. Cranney A., Wells G., Willan A. et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women // J. Endocrinology Review 2002. Vol. 23: 508-516.

26. Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial // J. Amecican Medical Association, 1998. Vol. 280: 2077-2082.

27. Devogelaer J.P., Broll H., Correa-Rotter R. et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis // J. Bone 1996. Vol. 18: 141-50.

28. Eastell R., Boyle I.T., Compston J., Cooper C., Fogelman I., Francis R.M., Hosking D.J., Purdie D.W., Ralston S., Reeve J., Reid D.M., Russell R.G.G., Stevenson J.C. Management of male osteoporosis: report of the UK Consensus Group // Quartely J Medicine, 1998. Vol. 91: 71-92.

29. Ettinger B., Martin J.S., Crans G., Pavo I.: Differential effects of Teriparatide on BMD after treatment with Raloxifene or Alendronate// J. Bone and Mineral Research. 2004. Vol. 19: 745-751

30. Eviö S., Tiitinen A., Laitinen K. et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. // J. Clinical Endocrinology Metabolism, 2003. Vol. 89(2): 626-631.

31. Finkelstein J.S., Hayes A., Hunzelman J. et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis // New England J Medicine, 2003. Vol.349: 1216-1226.

32. Fleisch H.: The use of bisphosphonates in osteoporosis, In Osteoporosis. Edited by J.C. Stevenson and R.Lindsay. 1998 Chapman & Hall Ltd, London, UK.

33. Gallagher J.C., Rapuri P.B., Haynatzki G., Detter J.R. Effect of discontinuation of estrogen, calcitriol, on bone density and bone markers // J. Clinical Endocrinology Metabolism, 2002. Vol. 87: 4914-4923.

34. Gonnelli S., Cepollaro C., Montagnani A. et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study // Calcified Tissue International 2003. Vol. 73(2): 133-139.

35. Granney A., Guyatt G., Griffith L. et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis // J. Endocrine Reviews, 2002. Vol. 23 (4): 570-578.

36. Greenspan S., Field-Munves E., Tonino R., et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study // Mayo Clinic Proccedings, 2002. Vol. 77: 1044-1052.

37. Greenspan S.L., Emkey R.D., Bone III H.G. et al. Significant differential effect of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis // J. Annual Internal Medicine 2002. Vol. 137: 875-883.

38. Greenspan S.L., Parker S.A., Ferguson L. et al. Early changes in biochemical markers on bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial // J. Bone Mineral Research, 1998. Vol. 13: 1431-1438.

39. Harrington J.T., Ste-Marie L.G., Brandi M.L. et al. Risendronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis // Calcific Tissue International, 2004. Vol. 74: 129-135

40. Health Care Guideline, Institute for Clinical Systems Improvement, Third Edition, July 2004, http:/

41. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents // J. Clinical Endocrinology Metabolism, 2002. Vol. 87: 1586-92.

42. Hochberg M.C., Ross P.D., Black D. et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis // J. Arthritis Rheumatology, 1999. Vol. 42: 1246-1254.

43. Homik J., Cranney A., Shea B. et al. Bisphosphonates for steroid induced osteoporosis (Cochrfflie Review), In; The Cochrane Library, Issue I, 2004.

44. Hosking D., Chilvers C.E.D., Christiansen C. et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age // New England J Medisine, 1998. Vol. 338: 485-492.

45. Institute for Clinical Systems Improvement. Health Care Guideline. Diagnosis and Treatment of osteoporosis //

46. Jacques P. 2002 clinical practice guidelines for diagnosis and management of osteoporosis in Canada.

47. Jacques P., Robert G. Josse, for the Scientific Advisory Council of the Osteoporosis Society of Canada // Canadian Medical Association J.,2002. Vol. 12. p.167.

48. Jenkins E.A., Walker-Bone K.E., Wood. et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate // Scandinavica J Rheumatology, 1999. Vol. 28: 152-156.

49. Johnell O., Scheele W.H., Lu Y., Reginster J.Y., Need A.G., Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis // J Clinical Endocrinology Metabolism 2002. 87(3): 985-92.

50. Kanis J.A., Johnel O., Oden A., Sernbo I., Redlund-Johnell I., Dawson A., Laet C., Jonsson B. Long-term risk of osteoporotic fracture in Malmo // J. Osteoporosis International, 2000. Vol. 11: 669-674.

51. Lau E.M., Woo J., Chan Y.H., Li M. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy // J. Bone 2001. Vol. 29: 506-10.

52. Liberman U.A., Weiss S.R., Broll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis // New England J. Medicine, 1995. Vol. 333: 1437-1443.

53. Lin J.H., Duggan D.E., Chen I.W. et al. Phisiological disposition of alendronate, a potent anti-osteolytic bisphosphonate in laboratory animals // J. Drug Metabolism Disposition 1991. Vol. 19: 926-932.

54. Lindsay R., Hart D.M., MacLean A., Clark A.C., Kraszewski A., Garwood J. Bone response to termination of oestrogen treatment // J. Lancet 1978. Vol. 1: 1325-1327.

55. McClung M., Clemmesen B., Daifotis A. et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group // J. Annual Internal Medicine 1998. Vol. 128: 253-261.

56. McClung M., Geusens P., Miller P. et al. Effect of risedronate on the risk of hip fracture in elderly women // New England J Medicine, 2001. Vol. 344: 333-340.

57. Miller P.D., Drezner M.K., Delmas P.D. et al. Monthly oral ibandronate is at leastas effective as oral daily ibandronate in postmenopausal osteoporosis: 1-year results from MOBILE // J Bone Mineral Research, 2004. Vol. 19: (Supl.1):S94 (Abstract F408).

58. Muhlbauer R.C., Bauss F., Schenk R. et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorbtion // J. Bone Mineral Research 1991. Vol. 6: 1003-1011.

59. Mulder H., Strays A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss // J. Rheumatology, 1994. Vol. 33: 348-350.

60. Orwoll E., Ettinger M., Weiss S. et al. Alendronate for the treatment of osteoporosis in men // New England J Medicine, 2000. Vol. 343: 604-610.

61. Palomba S., Orio F., Colao A. et al. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis // J. Clinical Endocrinology Metabolism 2002. Vol. 87: 1502-1508.

62. Papapoulos S.E., Landman J.O., Bijvoet O.L.M. The use of bisphosphonates in the treatment of osteoporosis // J. Bone, 1992. Vol. 13: S41-44.

63. Pols H.A.P., Felsenberg D., Hanley D.A. et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study // J. Osteoporos International 1999. Vol. 9: 461-468.

64. Reginster J.Y. et al. The MOPS study // J. Bone Mineral Research, 2003. Vol. 18 (Supl.2):S373.

65. Reginster J.Y., Minne H.W., Sorenson O.H. et al. Vertebral Efficacy Risedronate Therapy (VERT): randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis // J. Osteoporosis International, 2000. Vol. 11: 83-91.

66. Rittmaster R.S., Bolognese M., Ettinger M. et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate // J Clinical Endocrinology Metabolism, 2000. Vol. 85: 2129-2134.

67. Rizzoli et al. Two-years results of once-weekly administration of Alendronate 70 mg for the treatment of postmenopausal osteoporosis // J. Bone Mineral Research, 2002. Vol. 17: 1988-1996.

68. Russel R.J.J., Croucher P.J., Rogers M.J. Bisphosphonates; Pharmacology, mechanisms of action and clinical uses // J. Osteoporosis International, 1999. 9 (Suppl.2): S66-80.

69. Saag К.D., Schnitzer R., ,Brown T.J. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group // New England J. Medicine 1998;339:292-299.

70. Sambrook F.N., Kotowicz M., Nash P.,, Colin B., et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitrioli, vitamin D plus calcium, and alendronate plus calcium // J Bone Mineral Research, 2003. Vol. 18: 919-924.

71. Sambrook P.N., Rodriguez J.P., Wasnish R.D. et al. Alendronat in the prevention of osteoporosis: 7-year follow-up // J. Osteoporos International 2004. Vol. 15: 483-488.

72. Sato M., Grasser W., Endo N. et al. Bisphosphonates action: alendronate localization in rat bone and effects on osteoclast ultrastructure // J. Clinical Investigation, 1991. Vol. 88: 2095-2105.

73. Schnitzer T., Bone H.G., Grepaldi G. et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10mg daily in the treatment of osteoporosis // Aging Clinical Experimental Research, 2000. Vol. 12: 1-12.

74. Scottish Intercollegiate Guidelines Network, Management of osteoporosis. A national clinical guideline. June 2003, http:/

75. Sebba A.I., Bonnick S.L., Kagan R., Thompson D.E., Skalky C.S., Chen E., de Papp A.E. Fosamax Actonel Comparison Trial (FACT) investigators.: Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis // J. Current medical research and opinion, 2004. Vol. 20: 2031-2041.

76. Simon J.A., Lewiecki E.M., Smith M.E. et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study // Clinical Therapeutics, 2002. Vol. 24: 1871-86.

77. Tucci J.R., Tonino R.P., Emkey R.D., PeverlyC.A., Kher U., Santora A.C. II. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis // American J Medicine 1996. Vol. 101: 488-501.

78. Wasnich R.D., Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density // J Clinical Endocrinology Metabolism 2000. Vol. 85: 231-6.


Для цитирования:


For citation:

Dedov I.I., Rozhinskaya L.Y., Belaya Z.E. ROL' I MESTO BISFOSFONATOV V PROFILAKTIKE I LEChENII OSTEOPOROZA. 10-LETNIY OPYT PRIMENENIYa ALENDRONATA (FOSAMAKSA)Obzor literatury. Osteoporosis and Bone Diseases. 2005;8(1):20-30. (In Russ.)

Просмотров: 153

ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)